Discovery of novel 2-anilinopyrazolo[1,5-a]pyrimidine derivatives as c-Src kinase inhibitors for the treatment of acute ischemic stroke

Chemical and Pharmaceutical Bulletin

Volumn 55, Issue 6, 2007, Pages 881-889

  Mukaiyama, Harunobu ^a   Nishimura, Toshihiro ^a   Shiohara, Hiroaki ^a   Kobayashi, Satoko ^a   Komatsu, Yoshimitsu ^a   Kikuchi, Shinji ^a   Tsuji, Eiichi ^a   Kamada, Noboru ^a   Ohnota, Hideki ^a   Kusama, Hiroshi ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Acute ischemic stroke; c Src kinase; Central nervous system penetration; Pyrazolo 1,5 a pyrimidine

Indexed keywords

2 (3,5 DIMETHOXYPHENYLAMINO) 5 METHYL 7 (2 METHYLAMINOETHYLAMINO)PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 7 (2 AMINO 2 METHYLPROPYLAMINO) 2 (3 METHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 AMINO 2 METHYLPROPYLAMINO) 2 (3,5 DIMETHOXYPHENYLAMINO) 5 ETHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 AMINO 2 METHYLPROPYLAMINO) 2 (3,5 DIMETHOXYPHENYLAMINO) 5 ISOPROPYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 AMINO 2 METHYLPROPYLAMINO) 2 (3,5 DIMETHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 AMINO 2 METHYLPROPYLAMINO) 2 (3,5 DIMETHOXYPHENYLAMINO) 5 PHENYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 AMINO 2 METHYLPROPYLAMINO) 2 (3,5 DIMETHOXYPHENYLAMINO) 5 PROPYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 AMINO 2 METHYLPROPYLAMINO) 2 (4 METHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 AMINO 2 METHYLPROPYLAMINO) 5 CYCLOPROPYL 2 (3,5 DIMETHOXYPHENYLAMINO)PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 AMINO 2 METHYLPROPYLAMINO) 5 METHYL 2 PHENYLAMINOPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 AMINOPROPYLAMINO) 2 (3,5 DIMETHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (2 DIMETHYLAMINOETHYLAMINO) 2 (3,5 DIMETHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 (3 AMINOPROPYLAMINO) 2 (3,5 DIMETHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 CARBAMOYLMETHYLAMINO 2 (3,5 DIMETHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 CYCLOPROPYLMETHYLAMINO 2 (2 METHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 CYCLOPROPYLMETHYLAMINO 5 METHYL 2 PHENYLAMINOPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; [7 (2 AMINO 2 METHYLPROPYLAMINO) 3 CARBAMOYL 2 (3,5 DIMETHOXYPHENYLAMINO)PYRAZOLO[1,5 A]PYRIMIDINE 5 YL]ACETIC ACID; ADENOSINE TRIPHOSPHATE; ENZYME INHIBITOR; TERT BUTYL 2 [3 CARBAMOYL 2 (3,5 DIMETHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 YLAMINO] 1 METHYLETHYLCARBAMATE; TERT BUTYL 3 [3 CARBAMOYL 2 (3,5 DIMETHOXYPHENYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 YLAMINO]PROPYLCARBAMATE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTIMAL DRUG DOSE; RAT; STEREOCHEMISTRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CEREBROVASCULAR ACCIDENT; CRYSTALLOGRAPHY, X-RAY; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY, INFRARED; SRC-FAMILY KINASES;

EID: 34249994010     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.55.881     Document Type: Article

References (25)

1. Lyden P. D., Grotta J. C., Levine S. R., Marler J. R., Frankel M. R., Brott T. G., Neurology, 49, 14-20 (1997).
2. Thomas S. M., Brugge J. S., Annu. Rev. Cell Dev. Biol., 13, 513-609 (1997).
3. Yu X.-M., Askalan R., Keil II G. J., Salter M. W., Science, 275, 674-678 (1997).
4. Lu W.-Y., Xiong Z.-G., Lei S., Orser B. A., Dudek E., Browning M. D., MacDonald J. F., Nat. Neurosci., 2, 331-338 (1999).
5. Mócsai A., Ligeti E., Lowell C. A., Berton G., J. Immunol., 162, 1120-1126 (1999).
6. Jope R. S., Zhang L., Song L., Arch. Biochem. Biophys., 376, 365-370 (2000).
7. Zheng Z. G., Zhang L., Jiang Q., Zhang R., Davies K., Powers C., van Bruggen N., Chopp M., J. Clin. Invest., 106, 829-838 (2000).
8. Eliceiri B. P., Paul R., Schwartzberg P. L., Hood J. D., Leng J., Cheresh D. A., Mol. Cell, 4, 915-924 (1999).
9. Lennmyr F., Ericsson A., Gerwins P., Akterin S., Ahlström H., Terént A., Acta Neurol. Scand., 110, 175-179 (2004).
10. Paul R., Zhang Z. G., Eliceiri B. P., Jiang Q., Boccia A. D., Zhang R. L., Chopp M., Cheresh D. A., Nat. Med., 7, 222-227 (2001).
11. Akiyama C., Yuguchi T., Nishio M., Fujinaka T., Taniguchi M., Nakajima Y., Yoshimine T., Acta Neurochir., 86, 421-423 (2003).
12. Hanke J. H., Gardner J. P., Dow R. L., Changelian P. S., Brissette W. H., Weringer E. J., Pollok B. A., Connelly P. A., J. Biol. Chem., 271, 695-701 (1996).
13. Reid W., Abpul-Fetouh S., Chem.-Ztg., 113, 181-183 (1989).
14. Katritzky A. R., Pilarski B., Urogdi L., Synthesis, 12, 949-950 (1989).
15. Hisamichi H., Naito R., Toyoshima A., Kawano N., Ichikawa A., Orita A., Orita M., Hamada N., Takeuchi M., Ohta M., Tsukamoto S., Bioorg. Med. Chem., 13, 4936-4951 (2005).
16. Hirabayashi A., Mukaiyama H., Shiohara H., Kobayashi H., Terao Y., Miyazawa K., Misawa K., Oonoda H., Kokai Tokkyo Koho, JP 2004203748 (2004).
17. Mukaiyama H., Nishimura T., Kobayashi S., Ozawa T., Kamada N., Komatsu Y., Kikuchi S., Oonota H., Kusama H., Bioorg. Med. Chem., 15, 868-885 (2007).
18. Chen P., Norris D., Iwanowicz E. J., Spergel S. H., Lin J., Gu H. H., Shen Z., Wityak J., Lin T.-A., Pang S., De Fex H. F., Pitt S., Shen D. R., Doweyko A. M., Bassolino D. A., Roberge J. Y., Poss M. A., Chen B.-C., Schieven G. L., Barrish J. C., Bioorg. Med. Chem. Lett., 12, 1361-1364 (2002).
19. Fersht A., "Structure and Mechanism in Protein Science," 3rd ed., Chap. 11, W. H. Freeman and Company, New York, 2000, pp. 324-347.
20. Umemura K., Wada K., Uematsu T., Nakashima M., Stroke, 24, 1077-1081 (1993).
21. Sambrook J., Fritsch E. F., Maniatis T., "Molecular Cloning," 2nd ed., Vol. 3, Cold Spring Harbor Laboratory Press, New York, 1989, pp. 16-37.
22. Yamaguchi H., Hendrickson W. A., Nature (London), 384, 484-489 (1996).
23. Leslie A. G. W., Recent changes to the MOSFLM package for processing film and image plate data. "CCP4 and ESF-EACMB Newsletter on Protein Crystallography," No. 26, Daresbury Laboratory, Warrington, U.K., 1992.
24. Evans P. R., Data reduction. "Proceedings of the CCP4 Study Weekend. Data Collection & Processing," Daresbury Laboratory, Warrington, U.K., 1993, pp. 114-122.
25. Laskowski R. A., MacArthur M. W., Moss D. S., Thornton J. M., J. Appl. Crystallogr., 26, 283-291 (1993).